Preclinical studies in NSCLC showed that LILRB2 blockade reprograms immunosuppressive myeloid cells and promotes antitumour immunity via SHP1/2, AKT and STAT6 inhibition, suppressing granulocytic MDSCs and Treg infiltration and improving checkpoint inhibitor efficacy (160). Here, LILRB2 is linked to non-small cell lung carcinoma.